Pharma-biotech Licensing Trends to Watch for in 2021

In Vivo

"More option deals, greater use of alternative remedy clauses and aggressive diligence of assets. Geoffrey Spolyar, special counsel at Cooley, spotlights some of the changes he is seeing in pharma and biotech partnership agreements and explains why these trends matter in 2021."

Read the article

Related Contacts
Geoffrey Spolyar Special Counsel, Boston